Search PubMed⌕ Search

Biomedical subjects

K Torizuka

Publications and source records attributed to K Torizuka.

At least 379 records · Page 21Linked to original sources
PubMed1980

Thallium-201 myocardial scintigraphy: fractional uptake by the myocardium at rest and during exercise in patients with coronary artery disease and hypertrophic cardiomyopathy.

Fractional myocardial uptake of thallium-201 was estimated by routine scintigraphic evaluation at rest and during exercise in 10 control subjects, 15 patients with coronary artery disease (CAD) and 12 patients with hypertrophic cardiomyopathy (HCM). Fractional myocardial uptake of the total dose administered at rest was 3.59 +/- 0.98% in the controls, 4.43 +/- 1.17% in patients with CAD and 5.68 +/- 1.29% in patients with HCM, and uptake during exercise was 5.07 +/- 1.23% in the controls, 4.67 +/- 1.04% in the CAD group and 7.50 +/- 1.68% in the HCM group. The value in the HCM group was significantly higher than in the controls (P < 0.001 at rest) or in the CAD group (P < 0.02 at rest). A percentage increment of fractional uptake during exercise was significantly smaller in the CAD group than in the controls or the HCM group (P < 0.01). Thus, assessment of the fractional uptake appears to be a valuable adjunct to myocardial imaging when attempting a clinical assessment of CAD or HCM.

Adult↗
PubMed1980

[Enhancement of 67Ga tumor-to-blood ratios by chelating agent (author's transl)].

Chelating agent, such as CaEDTA, CaDTPA, D-penicillamine, DMSA, desferoxamine, NTA, cysteine ethyl ester, BAL, alpha-MPG, phthalein complexone, were tested as a possible contrast enhancing agent for tumor imaging with 67Ga-citrate. The intravenous administration of a chelating agent to Ehrlich's tumor bearing mice, one hour after the injection of 67Ga-citrate, accelerated the blood clearance with only a very slight change of activity in the target, increasing the tumor-to-blood ratio, and consequently achieving a better visualization. Among the tested chelating agents, D-penicillamine showed the highest target-to-nontarget ratio at a shorter time: a good tumor-to-blood ratio, performed after 24 hr with non-treated animals, was achieved in only 1-3 hr with post-treated animals. Thus, D-penicillamine hold a considerable promise as a contrast enhancing agent for future clinical use.

Animals↗
PubMed1980

[Scintigram].

Explore the source record for details and available documents.

Carcinoembryonic Antigen↗
PubMed1980

[Emission CT].

Explore the source record for details and available documents.

Carcinoma, Hepatocellular↗